Please login to the form below

Merz acquire BioForm Medical

Merz Pharma have agreed to acquire BioForm Medical for $253m, expanding its presence in cosmetic pharmaceuticals

Merz Pharma Group have agreed to acquire BioForm Medical Inc (BFRM) for $253m, expanding its cosmetic pharmaceuticals portfolio. The privately held German pharmaceutical company already has a presence in anti-ageing skincare with their product Belotero - the world's first monophasic hyaluronic acid dermal filler with patented CPM technology.

Merz will pay $5.45 per BioForm share, a 60 per cent premium to the company's Thursday closing price.

BioForm, which went public in late 2007, specialises in injectable drugs to improve the appearance of the skin, including treatment of wrinkles and folds, as well as varicose veins. The company is non profitable, though sales have been improving and last November BioForm narrowed its loss forecast for its fiscal year ending June 30.

6th January 2010

PME Digital Edition

Featured jobs

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Digital Account Director: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Great salary and benefits

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer: Salary TBC

Project Manager/ Account Manager: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Planner – Healthcare Advertising – New Role: Salary TBC

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...